Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. develops and manages licensed healthcare assets while advancing a pipeline of novel, multifunctional biotherapeutics for oncology. Company news centers on Ziihera (zanidatamab-hrii) and zanidatamab-related regulatory and clinical updates, including HER2-targeted development, as well as ZW191, a folate receptor alpha-targeting antibody-drug conjugate with Fast Track designation for advanced or metastatic platinum-resistant ovarian cancer.
Recurring updates also cover antibody-drug conjugate platform work, including RAS inhibitor ADC programs and targets such as CLDN18.2, Ly6E and PTK7, along with financial results, cash resources, share repurchase activity, investor conference participation and executive leadership appointments.
Zymeworks Inc. (NYSE: ZYME) reported its financial results for Q3 2020, revealing a revenue decrease to $2.6 million from $7.9 million in Q3 2019. The net loss widened to $72.6 million compared to $30.5 million the previous year. Key developments include the expansion of the zanidatamab pivotal trial into Europe and Asia-Pacific, as well as dosing the first patients in a Phase 2 trial for endometrial cancers. The company’s cash resources stand at $497 million, but it anticipates increased research and development expenses as clinical activities grow.